Brainsway (NASDAQ: BWAY) — Company Overview, News & Financial Data
Brainsway develops neurostimulation treatments for mental health using its advanced Deep TMS technology.
Brainsway
Brainsway (TLV:BWAY), (NASDAQ:BWAY) specializes in the development and marketing of advanced neurostimulation treatments for mental health disorders. The company's main focus is on its patented Deep Transcranial Magnetic Stimulation (Deep TMS) technology, a non-invasive treatment designed to target areas of the brain associated with mood and behavior disorders. Brainsway aims to improve the well-being of patients suffering from a variety of mental health conditions, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction, among others. Through continuous research and development, Brainsway strives to expand the applications of Deep TMS technology to address a wider range of neurological and psychiatric disorders, working towards the objective of offering effective, accessible, and safe treatment alternatives for patients worldwide.
Snapshot
Operations
Products and/or services of Brainsway
- Deep TMS Therapy - A non-invasive treatment for depression and OCD using magnetic fields to stimulate brain regions.
- Smoking Cessation - TMS technology aimed at helping individuals quit smoking.
- Obsessive-Compulsive Disorder Treatment - Offering a specialized TMS coil designed for patients with OCD.
- Alzheimer's Disease Management - Developing TMS solutions to alleviate symptoms of Alzheimer's disease.
- Anxiety Disorder Treatment - Utilizing TMS to reduce symptoms of various anxiety disorders.
- Bipolar Depression Treatment - Tailored TMS protocols to address the depressive phase in bipolar disorder patients.
Brainsway executive team
- Hadar LevyChief Executive Officer
- David ZacutCo-Founder & Vice-Chairman
- Abraham ZangenCo-Founder, Member of Scientific Advisory Board & Director
- Ido MaromChief Financial Officer
- Colleen HanlonVice President of Medical Affairs
- Michael CohenVice President of US Sales
- Yiftach RothFounder & Chief Scientific Officer
- Dor HagaiVice President of Operations
- Gilead MoiseyevChief Technology Officer
- Menachem C. KleinVP, General Counsel & Corporate Secretary
Latest news about Brainsway
Key financials
Reported results for Brainsway, in USD.
- Market cap
- 480.2M
- Revenue (TTM)
- 60.7M
- P/E ratio
- 51.9
- EPS (diluted, TTM)
- 0.2
- Dividend yield
- —
- Profit margin
- 15.6%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 52.2M | 4.3M | 7.6M | |
| 41M | 1.4M | 2.9M | |
| 31.8M | -5M | -4.2M | |
| 27.2M | -12.7M | -13.3M |